Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topotecan Plus WBRT vs WBRT Alone for Brain Metastases from NSCLC
NCT00390806Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2006
- Primary completion
- Jul 2012
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of topotecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by GSK. Primary endpoint: Overall Survival at 195 weeks. Started Dec 2006; status: completed.
02
Drugs
topotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00390806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390806.